Reynolds, C.; Masters, E.T.; Black-Shinn, J.; Boyd, M.; Mardekian, J.; Espirito, J.L.; Chioda, M.
Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study. J. Clin. Med. 2018, 7, 129.
https://doi.org/10.3390/jcm7060129
AMA Style
Reynolds C, Masters ET, Black-Shinn J, Boyd M, Mardekian J, Espirito JL, Chioda M.
Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study. Journal of Clinical Medicine. 2018; 7(6):129.
https://doi.org/10.3390/jcm7060129
Chicago/Turabian Style
Reynolds, Craig, Elizabeth T. Masters, Jenny Black-Shinn, Marley Boyd, Jack Mardekian, Janet L. Espirito, and Marc Chioda.
2018. "Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study" Journal of Clinical Medicine 7, no. 6: 129.
https://doi.org/10.3390/jcm7060129
APA Style
Reynolds, C., Masters, E. T., Black-Shinn, J., Boyd, M., Mardekian, J., Espirito, J. L., & Chioda, M.
(2018). Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study. Journal of Clinical Medicine, 7(6), 129.
https://doi.org/10.3390/jcm7060129